Table 2.
Parameter | OP (n = 17) | IP (n = 17) |
Margin | ||
Well- demarcated | 17 | 17 |
Ill- demarcated | 0 | 0 |
Shape | ||
Lobulated | 16 | 17 |
Irregular | 1 | 0 |
CT attenuation | ||
Hypodense | 0 | 0 |
Isodense | 17 | 17 |
Hyperdense | 0 | 0 |
T1WI | ||
Hypointense | 0 | 0 |
Isointense | 5 | 17 |
Hyperintense | 12 | 0 |
T2WI | ||
Hypointense | 0 | 0 |
Isointense | 13 | 17 |
Hyperintense | 4 | 0 |
Enhancement | ||
Mild | 0 | 0 |
Moderate | 17 | 17 |
Marked | 0 | 0 |
TIC pattern | ||
Type I | 0 | 0 |
Type II | 10 | 14 |
Type III | 0 | 0 |
DWI | ||
Hypointense | 1 | 1 |
Isointense | 1 | 4 |
Hyperintense |
DCE,dynamic contrast-enhanced; DWI, diffusion weighted imaging; IP, invertedpapilloma; OP, oncocytic papilloma; TIC, time intensity curve; T1WI, T1 weighted image; T2WI, T2 weighted image.
10 OPs and 14 IPs underwent DCE-MR imaging; 2 OPs and 5 IPs underwent DWI.